Tixagevimab/cilgavimab

Tixagevimab/cilgavimab is a combination of two monoclonal antibodies designed for the prevention and treatment of COVID-19. The combination is marketed under the brand name Evusheld by AstraZeneca. It was granted emergency use authorization by the FDA in the United States in December 2021.

Mechanism of Action

Tixagevimab and cilgavimab are monoclonal antibodies that bind to different, non-overlapping epitopes of the spike protein of SARS-CoV-2, the virus that causes COVID-19. By binding to the spike protein, they prevent the virus from entering human cells, thereby preventing infection.

Clinical Trials

The effectiveness of tixagevimab/cilgavimab was demonstrated in a Phase 3 clinical trial involving over 5,000 participants. The trial found that the combination reduced the risk of developing symptomatic COVID-19 by 77%.

Side Effects

Common side effects of tixagevimab/cilgavimab include injection site reactions, headache, and fatigue. Serious side effects are rare but can include allergic reactions.

Authorization

Tixagevimab/cilgavimab was granted emergency use authorization by the FDA in the United States in December 2021 for the pre-exposure prophylaxis (prevention) of COVID-19 in certain individuals.

See Also

• COVID-19 pandemic
• Monoclonal antibodies
• AstraZeneca

Tixagevimab/cilgavimab

• Tixagevimab-cilgavimab binding SARS-CoV-2 spike protein
  Tixagevimab-cilgavimab binding SARS-CoV-2 spike protein